<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="brief-report" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Russian Journal of Immunology</journal-id><journal-title-group><journal-title xml:lang="en">Russian Journal of Immunology</journal-title><trans-title-group xml:lang="ru"><trans-title>Российский иммунологический журнал</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1028-7221</issn><issn publication-format="electronic">2782-7291</issn><publisher><publisher-name xml:lang="en">Russian Society of Immunology</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">16718</article-id><article-id pub-id-type="doi">10.46235/1028-7221-16718-CGP</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>SHORT COMMUNICATIONS</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>КРАТКИЕ СООБЩЕНИЯ</subject></subj-group><subj-group subj-group-type="article-type"><subject>Short Communication</subject></subj-group></article-categories><title-group><article-title xml:lang="en">CD14 gene polymorphism in COVID-19 convalescents: analysis of (C-159)T</article-title><trans-title-group xml:lang="ru"><trans-title>Полиморфизм гена (C-159)T CD14 у реконвалесцентов COVID-19</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Yatskov</surname><given-names>I. A.</given-names></name><name xml:lang="ru"><surname>Яцков</surname><given-names>И. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>PhD (Medicine), Associate Professor, Department of Internal Medicine No. 2</p></bio><bio xml:lang="ru"><p>к.м.н., доцент кафедры внутренней медицины № 2</p></bio><email>ageevaeliz@rambler.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Beloglazov</surname><given-names>V. A.</given-names></name><name xml:lang="ru"><surname>Белоглазов</surname><given-names>В. А.</given-names></name></name-alternatives><bio xml:lang="en"><p>PhD, MD (Medicine), Professor, Head, Department of Internal Medicine No. 2</p></bio><bio xml:lang="ru"><p>д.м.н., профессор, заведующий кафедрой внутренней медицины № 2</p></bio><email>ageevaeliz@rambler.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Ageeva</surname><given-names>E. S.</given-names></name><name xml:lang="ru"><surname>Агеева</surname><given-names>Е. С.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>PhD, MD (Medicine), Associate Professor, Head, Department of Medical Biology</p></bio><bio xml:lang="ru"><p>д.м.н., доцент, заведующая кафедрой биологии медицинской</p></bio><email>ageevaeliz@rambler.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Rymarenko</surname><given-names>N. V.</given-names></name><name xml:lang="ru"><surname>Рымаренко</surname><given-names>Н. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>PhD, MD (Medicine), Professor, Professor, Department of Pediatrics with a Course in Childhood Infectious Diseases</p></bio><bio xml:lang="ru"><p>д.м.н., профессор, профессор кафедры педиатрии с курсом инфекционных болезней</p></bio><email>ageevaeliz@rambler.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Zhukova</surname><given-names>A. A.</given-names></name><name xml:lang="ru"><surname>Жукова</surname><given-names>А. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>PhD (Biology), Associate Professor, Department of Medical Biology</p></bio><bio xml:lang="ru"><p>к.б.н, доцент кафедры биологии медицинской</p></bio><email>ageevaeliz@rambler.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Ablayeva</surname><given-names>R. N.</given-names></name><name xml:lang="ru"><surname>Аблаева</surname><given-names>Р. Н.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Assistant professor, Department of Medical Biology</p></bio><bio xml:lang="ru"><p>ассистент кафедры биологии медицинской</p></bio><email>ageevaeliz@rambler.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Order of Labor Red Banner S. Georgievsky Medical Institute, V. Vernadsky Crimean Federal University</institution></aff><aff><institution xml:lang="ru">Ордена Трудового Красного Знамени Медицинский институт имени С.И. Георгиевского ФГАОУ ВО «Крымский федеральный университет имени В.И. Вернадского»</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2024-09-25" publication-format="electronic"><day>25</day><month>09</month><year>2024</year></pub-date><volume>27</volume><issue>3</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>683</fpage><lpage>688</lpage><history><date date-type="received" iso-8601-date="2024-03-29"><day>29</day><month>03</month><year>2024</year></date><date date-type="accepted" iso-8601-date="2024-04-06"><day>06</day><month>04</month><year>2024</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2024, Yatskov I.A., Beloglazov V.A., Ageeva E.S., Rymarenko N.V., Zhukova A.A., Ablayeva R.N.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2024, Яцков И.А., Белоглазов В.А., Агеева Е.С., Рымаренко Н.В., Жукова А.А., Аблаева Р.Н.</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="en">Yatskov I.A., Beloglazov V.A., Ageeva E.S., Rymarenko N.V., Zhukova A.A., Ablayeva R.N.</copyright-holder><copyright-holder xml:lang="ru">Яцков И.А., Белоглазов В.А., Агеева Е.С., Рымаренко Н.В., Жукова А.А., Аблаева Р.Н.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://rusimmun.ru/jour/article/view/16718">https://rusimmun.ru/jour/article/view/16718</self-uri><abstract xml:lang="en"><p>Cluster of differentiation 14 (CD14) is a pattern recognition receptor for lipopolysaccharide of gram-negative flora and has a close relationship with toll-like receptor 4 (TLR4). The interaction between CD14 and TLR 4 leads to the synthesis of cytokines such as interleukin-1, interleukin-6 and tumor necrosis factor-á. The TLR4 receptor is associated with the penetration of the new coronavirus infection virus into the cell, additionally stimulating the expression of the angiotensin converting enzyme 2 molecule and suppressing apoptosis in infected cells. Work on the study of the (159C)T polymorphism of the CD14 gene in COVID-19 is represented by only a few publications describing observations only in the Western European region. The purpose of our study was to study the association between single nucleotide polymorphism (SNP) of the CD14 gene – (159C)T (rs2569190) and susceptibility to a new coronavirus infection in the population of the Republic of Crimea. The study included 158 patients (87 women (55%) and 71 (45%) men, average age 45.6±6.14 years) who had COVID-19. Verification of previous COVID-19 was based on anamnestic data and data from studies performed at the time of illness (PCR). The control group consisted of 85 respondents who had not suffered a new coronavirus infection. To analyze the (C-159)T polymorphism of the CD14 gene, allele-specific PCR with electrophoretic detection in a 3% agarose gel (NPF "Litekh", Russia) was used. To compare the frequencies of allele combinations, the ÷<sup>2</sup> test and odds ratio (95% CI) were used. The distribution of CD14 mutations followed Hardy-Weinberg equilibrium (p &gt; 0.05). The results of the study showed that the distribution of CD14 gene genotypes did not differ significantly in all study groups. The dominant genotype was the heterozygous genotype CT of the (C-159)T polymorphism of the CD14 gene. The analysis showed that the presence of CT and TT SNPs was not associated with the risk of developing a new coronavirus infection (p &gt; 0.05). Conclusions. The CD14 SNP (C-159)T is not associated with a higher risk of COVID-19 infection. The distribution of occurrence of SNP variants in the group of recovered individuals did not differ significantly from that in the control group (p &gt; 0.05).</p></abstract><trans-abstract xml:lang="ru"><p>Кластер дифференцировки 14 (CD14) является паттерн-распознающим рецептором для липополисахарида грамнегативной флоры и имеет тесную взаимосвязь с толл-подобным рецептором 4-го типа (TLR4). Взаимодействие между CD14 и TLR4 приводит к синтезу таких цитокинов, как интерлейкин-1, интерлейкин-6 и фактор некроза опухоли-á. К тому же рецептор TLR4, по мнению ряда авторов, связан с процессом проникновения вируса новой коронавирусной инфекции в клетку, дополнительно стимулируя экспрессию основного «ключа» вируса – молекулы ангиотензин превращающего фермента 2 и подавляя апоптоз в инфицированных клетках. К сожалению, работы по изучению полиморфизма (159C) T-гена CD14 при COVID-19 представлены лишь единичными публикациями, описывающими наблюдения только в западноевропейском регионе. В связи с этим, целью нашего исследования было изучение ассоциации между однонуклеотидным полиморфизмом (ОНП) гена кластера дифференцировки 14 (CD14) – (159C) T (rs2569190) и восприимчивостью к новой коронавирусной инфекции в популяции Республики Крым. В исследование было включено 158 пациентов (87 женщин (55%) и 71 (45%) мужчина, средний возраст 45,6±6,14 лет), перенесших COVID-19, проходивших реабилитацию в постковидном периоде в пульмонологическом отделении ГБУЗ РК «АНИИ им. И.М. Сеченова». Верификация перенесенной инфекции COVID-19 была основана на анамнестических данных и данных, проведенных на момент заболевания исследований (ПЦР). Контрольная группа составила 85 здоровых респондентов, по данным анамнеза не перенесших новую коронавирусную инфекцию. Для анализа полиморфизма (C-159)T гена CD14 использовали аллель-специфическую ПЦР с электрофоретической детекцией в 3% агарозном геле (НПФ «Литех», Россия). Для сравнения частот комбинаций аллелей использовали критерий ÷<sup>2</sup> и отношение шансов (95% ДИ). Распределение мутаций CD14 соответствовало равновесию Харди–Вайнберга (p &gt; 0,05). Результаты исследования показали, что распределение полиморфных вариантов генотипов гена CD14 достоверно не отличалось во всех исследуемых группах. Доминирующим генотипом был гетерозиготный генотип CT полиморфизма (C-159)T гена CD14. Анализ показал, что наличие ОНП CT и TT не было ассоциировано с риском развития новой коронавирусной инфекции (p &gt; 0,05).</p> <p>ОНП (C-159)T гена CD14 не ассоциирован с более высоким риском заражения COVID-19. Распределения встречаемости вариантов ОНП в группе переболевших лиц достоверно не отличалось от такового в группе контроля (p &gt; 0,05).</p></trans-abstract><kwd-group xml:lang="en"><kwd>polymorphism</kwd><kwd>new coronavirus infection</kwd><kwd>(C-159)T</kwd><kwd>CD14</kwd><kwd>SARS-CoV-2</kwd><kwd>TLR4</kwd><kwd>single nucleotide polymorphism</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>полиморфизм</kwd><kwd>новая коронавирусная инфекция</kwd><kwd>(C-159)T</kwd><kwd>CD14</kwd><kwd>SARS-CoV-2</kwd><kwd>TLR4</kwd><kwd>однонуклеотидный полиморфизм</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution xml:lang="ru">Российский Научный Фонд</institution></institution-wrap><institution-wrap><institution xml:lang="en">Russian Science Foundation</institution></institution-wrap></funding-source><award-id>23-15-20021</award-id></award-group></funding-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Петров А.А., Страмбовская Н.Н., Говорин А.В., Витковский Ю.А. Генетический полиморфизм CD14, TNF и FCGR2A у больных гриппом A H1N1 в Забайкальском крае // Медицинская иммунология, 2011. Т.13, № 1. С. 83-86. [Petrov V.V., Strambovskaya N.N., Govorin A.V., Vitkovsky Yu.A. Genetic polymorphisms of CD14, TNF and FCGR2A in the patients with influenza A H1N1 in transbaikalia region. Meditsinskaya immunologiya = Medical Immunology (Russia), 2011, Vol. 13, no. 1, pp. 83-86. (In Russ.)] doi: 10.15789/1563-0625-2011-1-83-86.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Areeshi M.Y., Mandal R.K., Panda A.K., Bisht S.C., Haque S. CD14-159 C &gt; T gene polymorphism with increased risk of tuberculosis: evidence from a meta-analysis. PLoS One, 2013, Vol. 8, no. 5, e64747. doi: 10.1371/journal.pone.0064747.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Ayaslioglu E., Kalpaklioglu F., Kavut A.B., Erturk A., Capan N., Birben E. The role of CD14 gene promoter polymorphism in tuberculosis susceptibility. J. Microbiol. Immunol. Infect., 2013, Vol. 46, no. 3, pp. 158-163.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Choudhury A., Mukherjee S. In silico studies on the comparative characterization of the interactions of SARS-CoV-2 spike glycoprotein with ACE-2 receptor homologs and human TLRs. J. Med. Virol., 2020, Vol. 92, no. 10, pp. 2105-2113.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Karhukorpi J., Yan Y., Niemela S., Valtonen J., Koistinen P., Joensuu T. Effect of CD14 promoter polymorphism and H. pylori infection and its clinical outcomes on circulating CD14. Clin. Exp. Immunol., 2002, Vol. 128, no. 2, pp. 326-332.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Martinez F.D. CD14, endotoxin, and asthma risk: actions and interactions. Proc. Am. Thorac. Soc., 2007, Vol. 4, no. 3, pp. 221-225.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Meiler C., Muhlbauer M., Johann M., Hartmann A., Schnabl B., Wodarz N. Different effects of a CD14 gene polymorphism on disease outcome in patients with alcoholic liver disease and chronic hepatitis C infection. World J. Gastroenterol., 2005, Vol. 11, no. 38, pp. 6031-6037.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Moghadampour M., Eskandari-Nasab E., Shabani F. Relationship between CD14-159C/T gene polymorphism and acute brucellosis risk. Asian Pac. J. Trop. Med., 2016, Vol. 9, no. 3, pp. 247-251.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Panda A.K., Tripathy R., Das B. K. CD14 (C-159T) polymorphism is associated with increased susceptibility to SLE, and plasma levels of soluble CD14 is a novel biomarker of disease activity: A hospital-based case-control study. Lupus, 2021, Vol. 30, no. 2, pp. 219-227.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Pati A., Padhi S., Panda D., Suvankar S., Panda A.K. A CD14 Polymorphism (C-159T rs2569190) Is Associated with SARS-CoV-2 Infection and Mortality in the European Population. J. Infect. Dis., 2021, Vol. 224, no. 5, pp. 921-922.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Rupp J., Goepel W., Kramme E., Jahn J., Solbach W., Maass M. CD14 promoter polymorphism -159C &gt; T is associated with susceptibility to chronic Chlamydia pneumoniae infection in peripheral blood monocytes. Genes Immun., 2004, Vol. 5, no. 5, pp. 435-438.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Teixeira J.P., Barone S., Zahedi K., Soleimani M. Kidney Injury in COVID-19: Epidemiology, Molecular Mechanisms and Potential Therapeutic Targets. Int. J. Mol. Sci., 2022, Vol. 23, no. 4, 2242. doi: 10.3390/ijms23042242.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Wu Z., Zhang Z., Lei Z., Lei P. CD14: Biology and role in the pathogenesis of disease. Cytokine Growth Factor Rev., 2019, Vol. 48, pp. 24-31.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Yuan F.F., Boehm I., Chan P.K., Marks K., Tang J.W., Hui D.S. High prevalence of the CD14-159CC genotype in patients infected with severe acute respiratory syndrome-associated coronavirus. Clin. Vaccine Immunol., 2007, Vol. 14, no. 12, pp. 1644-1645.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Zanoni I., Granucci F. Role of CD14 in host protection against infections and in metabolism regulation. Front. Cell. Infect. Microbiol., 2013, Vol. 3, 32. doi: 10.3389/fcimb.2013.00032.</mixed-citation></ref></ref-list></back></article>
